Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

Bibliografske podrobnosti
Main Authors:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
Format:	Journal article
Jezik:	English
Izdano:	2002

Podobne knjige/članki

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
od: Eaton, C, et al.
Izdano: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
od: Eaton, C, et al.
Izdano: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
od: Holen, I, et al.
Izdano: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
od: Holen, I, et al.
Izdano: (2002)

Role of osteoprotegerin (OPG) in cancer.
od: Holen, I, et al.
Izdano: (2006)

The role of osteoprotegerin in breast and prostate cancer
od: Holen, I, et al.
Izdano: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
od: Holen Ingunn, et al.
Izdano: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
od: Shipman, C, et al.
Izdano: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
od: Lili Zhang, et al.
Izdano: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
od: Shipman, C, et al.
Izdano: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
od: Shipman, C, et al.
Izdano: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
od: Gamal B Mohamed, et al.
Izdano: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
od: Waterman, E, et al.
Izdano: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
od: Miles, L, et al.
Izdano: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
od: Croucher, P, et al.
Izdano: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
od: Noura N. Alraouji, et al.
Izdano: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
od: Riham Eid, et al.
Izdano: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
od: Shipman, C, et al.
Izdano: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
od: Siamak Kazemi-Sufi, et al.
Izdano: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
od: Nyambo, R, et al.
Izdano: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
od: Nyambo, R, et al.
Izdano: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
od: Chan Kai-Ming, et al.
Izdano: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
od: Syed Muhammad Muneeb Akhtar, et al.
Izdano: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
od: Croucher, P, et al.
Izdano: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
od: Yao Jing, et al.
Izdano: (2011-03-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
od: Yosra Azizpour, et al.
Izdano: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
od: Yosra Azizpour, et al.
Izdano: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
od: Ruffion, A, et al.
Izdano: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
od: Lara Absil, et al.
Izdano: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
od: Indra Wijaya, et al.
Izdano: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
od: Croucher, P, et al.
Izdano: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
od: Croucher, P, et al.
Izdano: (2001)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
od: Lane Denis, et al.
Izdano: (2012-11-01)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
od: Shirly Elisa Tedjasaputra, et al.
Izdano: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
od: Salvador Atilano-Miguel, et al.
Izdano: (2022-01-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
od: Martin Widschwendter, et al.
Izdano: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
od: Cross, N, et al.
Izdano: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
od: Cross, N, et al.
Izdano: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
od: Vanderkerken, K, et al.
Izdano: (2003)

The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis
od: Yousif Pshtiwan A., et al.
Izdano: (2023-01-01)